α-Pyrrolidinopentiophenone (alpha-pyrrolidinovalerophenone, α-PVP, alpha-PVP, O-2387, β-ketone-prolintane, Prolintanone) is a stimulant compound developed in the 1960s and related to pyrovalerone and is the ketone analog of prolintane.
The mechanism of action is unknown for α-pyrrolidinopentiophenone. α-PVP is believed to act similarly to the designer drug MDPV, which acts as a norepinephrine-dopamine reuptake inhibitor (NDRI), although no substantial research on this compound has been conducted.
α-PVP is a Schedule I drug in New Mexico, Delaware, Oklahoma, and Virginia. On January 28, 2014, the DEA listed it, along with 9 other synthetic cathinones, on the Schedule 1 with a temporary ban, effective February 27, 2014. The Drug was explicitly made illegal in New South Wales after it was illegally marketed with the imprimatur of erroneous legal advice that it was not encompassed by analog provisions of the relevant act. It is encompassed by those provisions, and therefore has been illegal for many years in New South Wales. The legislative action followed the death of two individuals from using it; one jumping off a balcony, another having a heart attack after a state of delirium. It is sometimes the active ingredient in a drug often referred to colloquially as "bath salts".
α-PVP has been linked to at least one death where it was combined with pentedrone and caused heart failure.
§See also
- MDPV
- Naphyrone (O-2482)
- Pentedrone
- Pentylone
- Prolintane
- Pyrovalerone (O-2371)
§References
